Antiviral Immunity of Bacteria
Our Research
Antiviral Bacterial Immunity
Bacteriophages show strong potential as treatments for bacterial infections, but their clinical use is limited by specificity: they often infect only certain bacterial strains and are unable to kill other clinical isolates. One of the main reasons for this phage specificity is the emergence of unique antiviral protective barriers in different bacterial strains, which make them resistant to phages. Bacterial antiviral immune systems are highly diverse. To better withstand surrounding viral threats, bacterial strains constantly acquire immune genes by inserting mobile genetic elements, such as transposons, into their genomes. This leads to the emergence of immune gene clusters, “defense islands”, which could include dozens of different antiviral genes. We study how “defense islands” form, how they are regulated, and how they provide antiviral protection, using clinical strains of Pseudomonas aeruginosa and Burkholderia cenocepacia. Our goal is to identify the barriers phages face and enhance bacteriophages to overcome them, enabling more efficient phage therapy.
Anti-immune phage genes
Similar to bacteria, phages use horizontal gene transfer to acquire genes that allow them to counter bacterial defenses and overcome bacterial immunity. These genes are often encoded in phage genomes as anti-defense hotspots. Using genetic and biochemical approaches, we aim to understand the role of these anti-defense genes in phage infectivity.